PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.

PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.

Item
http://www.wikidata.org/entity/Q36196833
Atherogenesis and metabolic dysregulation in LDL receptor-knockout rats.PCSK9 and Atherosclerosis - Lipids and Beyond.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Local effects of human PCSK9 on the atherosclerotic lesion.Novel method for reducing plasma cholesterol: a ligand replacement therapy.Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.Episomal Nonviral Gene Therapy Vectors Slow Progression of Atherosclerosis in a Model of Familial Hypercholesterolemia.Comment on "Hypercholesterolemia with consumption of PFOA-laced Western diets is dependent on strain and sex of mice" by Rebholz S.L. et al. Toxicol. Rep. 2016 (3) 46-54.PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction.The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice.Non-Native Conformational Isomers of the Catalytic Domain of PCSK9 Induce an Immune Response, Reduce Lipids and Increase LDL Receptor Levels.Reduced Blood Lipid Levels With In Vivo CRISPR-Cas9 Base Editing of ANGPTL3.The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model.Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease
P2860

PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.

Item
http://www.wikidata.org/entity/Q36196833
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
PCSK9 inhibition fails to alte ...... erosis in the absence of ApoE.
@ast
PCSK9 inhibition fails to alte ...... erosis in the absence of ApoE.
@en
type
label
PCSK9 inhibition fails to alte ...... erosis in the absence of ApoE.
@ast
PCSK9 inhibition fails to alte ...... erosis in the absence of ApoE.
@en
prefLabel
PCSK9 inhibition fails to alte ...... erosis in the absence of ApoE.
@ast
PCSK9 inhibition fails to alte ...... erosis in the absence of ApoE.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P932
P356
P1433
P1476
PCSK9 inhibition fails to alte ...... lerosis in the absence of ApoE
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P932